ADVERTISEMENT
ADVERTISEMENT
Jeeva Clinical Trials acquires AI platform Clintelligence
The acquisition adds predictive analytics and patient-matching tools to Jeeva’s unified clinical trial platform.
-
1759953093.png)
Staff Reporter - Wed, 13, May 2026
- 17:20 EDT
- 30
Jeeva acquires Clintelligence / Jeeva Clinical Trials Inc
Virginia-based health-tech company Jeeva Clinical Trials announced the acquisition of AI-powered clinical trial intelligence platform Clintelligence, expanding its capabilities in protocol design, patient recruitment, and trial risk prediction.
The acquisition integrates Clintelligence’s artificial intelligence tools and historical clinical trial database into Jeeva’s unified clinical trial platform, enabling sponsors to design, optimize, and execute clinical trials within a single system, the firm said.
Also Read: Jeeva Clinical Trials launches AI program for academic centers
Jeeva also said the acquisition adds predictive intelligence to the early stages of clinical development, where delays and failures are often determined. The integrated platform will support protocol development, patient enrollment, data capture, and study completion through a connected system.
“The biggest inefficiencies in clinical trials are not just operational, they are foundational,” said Harsha K. Rajasimha, founder and CEO of Jeeva Clinical Trials.
"Protocol complexity and suboptimal design remain the leading drivers of delays, amendments, and trial failures. Clintelligence brings predictive intelligence to the front of the lifecycle, enabling sponsors to identify risks early, optimize design, and move forward with confidence. This is a transformative step toward faster, smarter, and more patient-centric trials,” he added.
Industry data cited by the company showed that around 85 percent of clinical trials experience delays, more than half require protocol amendments, and nearly one-third terminate early because of design and recruitment challenges. Jeeva said each protocol amendment can cost more than $500,000 and add months to study timelines.
According to the company, Clintelligence analyzes data from more than one million historical clinical studies to predict amendment likelihood, enrollment delays, and termination risks. Jeeva said the platform has demonstrated up to 85 percent accuracy in predicting trial risks and can generate average savings of approximately $350,000 per study.
“Thirty percent of clinical trials fail predictably and 85 percent are delayed, but those failures and delays are often preventable,” said Agam Bansal, founder of Clintelligence. “Our mission at Clintelligence is to use the power of AI to learn from historical trials’ outcomes data and avoid costly mistakes.”
The acquisition also strengthens Jeeva’s patient recruitment and site selection capabilities. Clintelligence’s patient-matching engine allows patients to search for trials using natural language and generates eligibility-based screening questions to identify suitable studies.
The company said the platform also profiles more than 50,000 research sites across over 150 countries, ranking them based on enrollment performance, therapeutic expertise, and competitive saturation. Machine learning-based forecasting tools provide enrollment projections and feasibility analysis for sponsors.
Jeeva said the combined platform integrates protocol design, patient recruitment, eConsent, electronic data capture, electronic patient-reported outcomes, scheduling, monitoring, and analytics into a single system for sponsors, contract research organizations, and research sites.
Discover more at New India Abroad.
Related
ADVERTISEMENT
ADVERTISEMENT
E Paper
Video
Comments
Start the conversation
Become a member of New India Abroad to start commenting.
Sign Up Now
Already have an account? Login